Group sequential clinical trials for longitudinal data with analyses using summary statistics

Longitudinal endpoints are used in clinical trials, and the analysis of the results is often conducted using within‐individual summary statistics. When these trials are monitored, interim analyses that include subjects with incomplete follow‐up can give incorrect decisions due to bias by non‐lineari...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Statistics in medicine 2005-08, Vol.24 (16), p.2457-2475
Hauptverfasser: Kittelson, John M., Sharples, Katrina, Emerson, Scott S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2475
container_issue 16
container_start_page 2457
container_title Statistics in medicine
container_volume 24
creator Kittelson, John M.
Sharples, Katrina
Emerson, Scott S.
description Longitudinal endpoints are used in clinical trials, and the analysis of the results is often conducted using within‐individual summary statistics. When these trials are monitored, interim analyses that include subjects with incomplete follow‐up can give incorrect decisions due to bias by non‐linearity in the true time trajectory of the treatment effect. Linear mixed‐effects models can be used to remove this bias, but there is a lack of software to support both the design and implementation of monitoring plans in this setting. This paper considers a clinical trial in which the measurement time schedule is fixed (at least for pre‐trial design), and the scientific question is parameterized by a contrast across these measurement times. This setting assures generalizable inference in the presence of non‐linear time trajectories. The distribution of the treatment effect estimate at the interim analyses using the longitudinal outcome measurements is given, and software to calculate the amount of information at each interim analysis is provided. The interim information specifies the analysis timing thereby allowing standard group sequential design software packages to be used for trials with longitudinal outcomes. The practical issues with implementation of these designs are described; in particular, methods are presented for consistent estimation of treatment effects at the interim analyses when outcomes are not measured according to the pre‐trial schedule. Splus/R functions implementing this inference using appropriate linear mixed‐effects models are provided. These designs are illustrated using a clinical trial of statin treatment for the symptoms of peripheral arterial disease. Copyright © 2005 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/sim.2127
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68083682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>883572431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4187-53032f7ad674cc6389c6299725d14d33f8eefcad73fe9e5b6f9fcac5576a4b7a3</originalsourceid><addsrcrecordid>eNp1kF1rFDEUhoModq2Cv0CCF-LN1HxMcmYutei00FawWwqChGwmU1PnY83JUPffm2UHBcGr5D08vPA-hLzk7IQzJt5hGE4EF_CIrDiroWBCVY_JigmAQgNXR-QZ4j1jnCsBT8kRVzWAqNWKfGviNG8p-p-zH1OwPXV9GIPLnxRzRNpNkfbTeBfS3IYx31ubLH0I6Tu1Oe7QI50xjHcU52GwcUcx2RQwBYfPyZMud_gXy3tMbj59XJ-eFRefm_PT9xeFK3kFhZJMig5sq6F0TsuqdlrUNQjV8rKVsqu875xtQXa-9mqjuzpHpxRoW27AymPy5tC7jVMegskMAZ3vezv6aUajK1ZJXYkMvv4HvJ_mmGegEULyUjDNM_T2ALk4IUbfmW0M-2WGM7P3bbJvs_ed0VdL37wZfPsXXARnoDgAD6H3u_8Wmevzy6Vw4bNA_-sPb-MPo0GCMrdXjVk3X9fXXz6cmUb-Bhlrmmg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223142061</pqid></control><display><type>article</type><title>Group sequential clinical trials for longitudinal data with analyses using summary statistics</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Kittelson, John M. ; Sharples, Katrina ; Emerson, Scott S.</creator><creatorcontrib>Kittelson, John M. ; Sharples, Katrina ; Emerson, Scott S.</creatorcontrib><description>Longitudinal endpoints are used in clinical trials, and the analysis of the results is often conducted using within‐individual summary statistics. When these trials are monitored, interim analyses that include subjects with incomplete follow‐up can give incorrect decisions due to bias by non‐linearity in the true time trajectory of the treatment effect. Linear mixed‐effects models can be used to remove this bias, but there is a lack of software to support both the design and implementation of monitoring plans in this setting. This paper considers a clinical trial in which the measurement time schedule is fixed (at least for pre‐trial design), and the scientific question is parameterized by a contrast across these measurement times. This setting assures generalizable inference in the presence of non‐linear time trajectories. The distribution of the treatment effect estimate at the interim analyses using the longitudinal outcome measurements is given, and software to calculate the amount of information at each interim analysis is provided. The interim information specifies the analysis timing thereby allowing standard group sequential design software packages to be used for trials with longitudinal outcomes. The practical issues with implementation of these designs are described; in particular, methods are presented for consistent estimation of treatment effects at the interim analyses when outcomes are not measured according to the pre‐trial schedule. Splus/R functions implementing this inference using appropriate linear mixed‐effects models are provided. These designs are illustrated using a clinical trial of statin treatment for the symptoms of peripheral arterial disease. Copyright © 2005 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0277-6715</identifier><identifier>EISSN: 1097-0258</identifier><identifier>DOI: 10.1002/sim.2127</identifier><identifier>PMID: 15977295</identifier><identifier>CODEN: SMEDDA</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>area under curve ; clinical trial ; Clinical trials ; Data analysis ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Linear Models ; longitudinal endpoint ; Longitudinal Studies ; mixed-effects model ; Peripheral Vascular Diseases - drug therapy ; Randomized Controlled Trials as Topic - methods ; Software ; Statistical analysis ; Walking - physiology</subject><ispartof>Statistics in medicine, 2005-08, Vol.24 (16), p.2457-2475</ispartof><rights>Copyright © 2005 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright 2005 John Wiley &amp; Sons, Ltd</rights><rights>Copyright John Wiley and Sons, Limited Aug 30, 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4187-53032f7ad674cc6389c6299725d14d33f8eefcad73fe9e5b6f9fcac5576a4b7a3</citedby><cites>FETCH-LOGICAL-c4187-53032f7ad674cc6389c6299725d14d33f8eefcad73fe9e5b6f9fcac5576a4b7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fsim.2127$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fsim.2127$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15977295$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kittelson, John M.</creatorcontrib><creatorcontrib>Sharples, Katrina</creatorcontrib><creatorcontrib>Emerson, Scott S.</creatorcontrib><title>Group sequential clinical trials for longitudinal data with analyses using summary statistics</title><title>Statistics in medicine</title><addtitle>Statist. Med</addtitle><description>Longitudinal endpoints are used in clinical trials, and the analysis of the results is often conducted using within‐individual summary statistics. When these trials are monitored, interim analyses that include subjects with incomplete follow‐up can give incorrect decisions due to bias by non‐linearity in the true time trajectory of the treatment effect. Linear mixed‐effects models can be used to remove this bias, but there is a lack of software to support both the design and implementation of monitoring plans in this setting. This paper considers a clinical trial in which the measurement time schedule is fixed (at least for pre‐trial design), and the scientific question is parameterized by a contrast across these measurement times. This setting assures generalizable inference in the presence of non‐linear time trajectories. The distribution of the treatment effect estimate at the interim analyses using the longitudinal outcome measurements is given, and software to calculate the amount of information at each interim analysis is provided. The interim information specifies the analysis timing thereby allowing standard group sequential design software packages to be used for trials with longitudinal outcomes. The practical issues with implementation of these designs are described; in particular, methods are presented for consistent estimation of treatment effects at the interim analyses when outcomes are not measured according to the pre‐trial schedule. Splus/R functions implementing this inference using appropriate linear mixed‐effects models are provided. These designs are illustrated using a clinical trial of statin treatment for the symptoms of peripheral arterial disease. Copyright © 2005 John Wiley &amp; Sons, Ltd.</description><subject>area under curve</subject><subject>clinical trial</subject><subject>Clinical trials</subject><subject>Data analysis</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Linear Models</subject><subject>longitudinal endpoint</subject><subject>Longitudinal Studies</subject><subject>mixed-effects model</subject><subject>Peripheral Vascular Diseases - drug therapy</subject><subject>Randomized Controlled Trials as Topic - methods</subject><subject>Software</subject><subject>Statistical analysis</subject><subject>Walking - physiology</subject><issn>0277-6715</issn><issn>1097-0258</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kF1rFDEUhoModq2Cv0CCF-LN1HxMcmYutei00FawWwqChGwmU1PnY83JUPffm2UHBcGr5D08vPA-hLzk7IQzJt5hGE4EF_CIrDiroWBCVY_JigmAQgNXR-QZ4j1jnCsBT8kRVzWAqNWKfGviNG8p-p-zH1OwPXV9GIPLnxRzRNpNkfbTeBfS3IYx31ubLH0I6Tu1Oe7QI50xjHcU52GwcUcx2RQwBYfPyZMud_gXy3tMbj59XJ-eFRefm_PT9xeFK3kFhZJMig5sq6F0TsuqdlrUNQjV8rKVsqu875xtQXa-9mqjuzpHpxRoW27AymPy5tC7jVMegskMAZ3vezv6aUajK1ZJXYkMvv4HvJ_mmGegEULyUjDNM_T2ALk4IUbfmW0M-2WGM7P3bbJvs_ed0VdL37wZfPsXXARnoDgAD6H3u_8Wmevzy6Vw4bNA_-sPb-MPo0GCMrdXjVk3X9fXXz6cmUb-Bhlrmmg</recordid><startdate>20050830</startdate><enddate>20050830</enddate><creator>Kittelson, John M.</creator><creator>Sharples, Katrina</creator><creator>Emerson, Scott S.</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20050830</creationdate><title>Group sequential clinical trials for longitudinal data with analyses using summary statistics</title><author>Kittelson, John M. ; Sharples, Katrina ; Emerson, Scott S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4187-53032f7ad674cc6389c6299725d14d33f8eefcad73fe9e5b6f9fcac5576a4b7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>area under curve</topic><topic>clinical trial</topic><topic>Clinical trials</topic><topic>Data analysis</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Linear Models</topic><topic>longitudinal endpoint</topic><topic>Longitudinal Studies</topic><topic>mixed-effects model</topic><topic>Peripheral Vascular Diseases - drug therapy</topic><topic>Randomized Controlled Trials as Topic - methods</topic><topic>Software</topic><topic>Statistical analysis</topic><topic>Walking - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kittelson, John M.</creatorcontrib><creatorcontrib>Sharples, Katrina</creatorcontrib><creatorcontrib>Emerson, Scott S.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Statistics in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kittelson, John M.</au><au>Sharples, Katrina</au><au>Emerson, Scott S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Group sequential clinical trials for longitudinal data with analyses using summary statistics</atitle><jtitle>Statistics in medicine</jtitle><addtitle>Statist. Med</addtitle><date>2005-08-30</date><risdate>2005</risdate><volume>24</volume><issue>16</issue><spage>2457</spage><epage>2475</epage><pages>2457-2475</pages><issn>0277-6715</issn><eissn>1097-0258</eissn><coden>SMEDDA</coden><abstract>Longitudinal endpoints are used in clinical trials, and the analysis of the results is often conducted using within‐individual summary statistics. When these trials are monitored, interim analyses that include subjects with incomplete follow‐up can give incorrect decisions due to bias by non‐linearity in the true time trajectory of the treatment effect. Linear mixed‐effects models can be used to remove this bias, but there is a lack of software to support both the design and implementation of monitoring plans in this setting. This paper considers a clinical trial in which the measurement time schedule is fixed (at least for pre‐trial design), and the scientific question is parameterized by a contrast across these measurement times. This setting assures generalizable inference in the presence of non‐linear time trajectories. The distribution of the treatment effect estimate at the interim analyses using the longitudinal outcome measurements is given, and software to calculate the amount of information at each interim analysis is provided. The interim information specifies the analysis timing thereby allowing standard group sequential design software packages to be used for trials with longitudinal outcomes. The practical issues with implementation of these designs are described; in particular, methods are presented for consistent estimation of treatment effects at the interim analyses when outcomes are not measured according to the pre‐trial schedule. Splus/R functions implementing this inference using appropriate linear mixed‐effects models are provided. These designs are illustrated using a clinical trial of statin treatment for the symptoms of peripheral arterial disease. Copyright © 2005 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>15977295</pmid><doi>10.1002/sim.2127</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0277-6715
ispartof Statistics in medicine, 2005-08, Vol.24 (16), p.2457-2475
issn 0277-6715
1097-0258
language eng
recordid cdi_proquest_miscellaneous_68083682
source MEDLINE; Access via Wiley Online Library
subjects area under curve
clinical trial
Clinical trials
Data analysis
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Linear Models
longitudinal endpoint
Longitudinal Studies
mixed-effects model
Peripheral Vascular Diseases - drug therapy
Randomized Controlled Trials as Topic - methods
Software
Statistical analysis
Walking - physiology
title Group sequential clinical trials for longitudinal data with analyses using summary statistics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T11%3A15%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Group%20sequential%20clinical%20trials%20for%20longitudinal%20data%20with%20analyses%20using%20summary%20statistics&rft.jtitle=Statistics%20in%20medicine&rft.au=Kittelson,%20John%20M.&rft.date=2005-08-30&rft.volume=24&rft.issue=16&rft.spage=2457&rft.epage=2475&rft.pages=2457-2475&rft.issn=0277-6715&rft.eissn=1097-0258&rft.coden=SMEDDA&rft_id=info:doi/10.1002/sim.2127&rft_dat=%3Cproquest_cross%3E883572431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223142061&rft_id=info:pmid/15977295&rfr_iscdi=true